Stock comparison
Indivior Pharmaceuticals
LeMaitre Vascular
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
INDV
Indivior Pharmaceuticals
Market cap
$4.68B
Sector
Healthcare
LMAT
LeMaitre Vascular
Market cap
$2.23B
Sector
Healthcare
Overall winner
LeMaitre Vascular LMAT
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | INDV | LMAT | Winner |
|---|---|---|---|
| Warren Buffett | 35D | 77B | LMAT |
| Benjamin Graham | 30F | 89A | LMAT |
| Philip Fisher | 44D | 81C | LMAT |
| Peter Lynch | 71B | 67B | INDV |
| Joel Greenblatt | 78B | 56D | INDV |
| Charlie Munger | 50D | 68D | LMAT |
| Terry Smith | 46D | 69D | LMAT |
Side-by-side metrics
| Metric | INDV | LMAT |
|---|---|---|
| Market cap | $4.68B | $2.23B |
| P/E (TTM) | 19.0x | 37.1x |
| EV/EBIT | 19.1x | 36.6x |
| ROIC (TTM) | 85.68% | 9.43% |
| Gross margin | 83.11% | 72.39% |
| Net margin | 19.44% | 24.35% |
| Revenue CAGR 5y | 11.87% | 12.75% |
| EPS CAGR 5y | 5.04% | 19.04% |
| Debt / Equity | - | 0.5x |
| Dividend yield | 0.0% | 0.84% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
INDV leads on
- Debt / Equity-vs 0.5x+113%
- ROIC (TTM)85.68%vs 9.43%+89%
- Market cap$4.68Bvs $2.23B+52%
- P/E (TTM)19.0xvs 37.1x+49%
LMAT leads on
- Dividend yield0.84%vs 0.0%+100%
- EPS CAGR 5y19.04%vs 5.04%+74%
- Net margin24.35%vs 19.44%+20%
- Revenue CAGR 5y12.75%vs 11.87%+7%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.